Clinical efficacy of PARP inhibitors in breast cancer-Reference-Cited by-同舟云学术

Clinical efficacy of PARP inhibitors in breast cancer

Published:2023-05-02 Issue:1 Volume:200 Page:15-22
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Pandya Karan,Scher Alyssa,Omene Coral,Ganesan Shridar,Kumar Shicha,Ohri Nisha,Potdevin Lindsay,Haffty Bruce,Toppmeyer Deborah L.,George Mridula A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-023-06940-0.pdf

Reference41 articles.

1. Rose M et al (2020) PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol 8:564601

2. Yi M et al (2019) Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 8:29

3. Casaubon JT, Kashyap S, Regan JP (2022) BRCA 1 and 2. StatPearls, Treasure Island

4. Tutt ANJ et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394–2405

5. RayChaudhuri A, Nussenzweig A (2017) The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 18(10):610–621

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma;Medicina;2024-03-31

2. Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux;Pharmacological Research;2024-02

3. Assessing the Phenotype of a Homologous Recombination Deficiency Using High Resolution Array-Based Comparative Genome Hybridization in Ovarian Cancer;International Journal of Molecular Sciences;2023-12-14

4. Double‐strand DNA break repair: molecular mechanisms and therapeutic targets;MedComm;2023-10